Novavax Expects Full Year 2024 Revenue Of $800M-$1B Versus Consensus Of $969.56M, With Combined R&D and SG&A Expenses Of $700M-$800M
Portfolio Pulse from Benzinga Newsdesk
Novavax projects its full-year 2024 revenue to be between $800 million and $1 billion, aligning closely with the consensus estimate of $969.56 million. The company also anticipates its combined Research & Development (R&D) and Selling, General & Administrative (SG&A) expenses to range from $700 million to $800 million.
February 28, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Novavax expects its 2024 revenue to be in the range of $800M to $1B, with consensus estimates at $969.56M. Anticipated R&D and SG&A expenses are between $700M and $800M.
Novavax's revenue projection for 2024 aligns closely with market consensus, indicating a neutral impact on its stock price in the short term. The anticipated expenses suggest the company is managing its costs effectively, which could be viewed positively by investors. However, the close alignment with consensus means there may not be significant surprises to drive stock price movements.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100